azacitidine has been researched along with Acute Disease in 95 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 28 (29.47) | 18.7374 |
| 1990's | 11 (11.58) | 18.2507 |
| 2000's | 25 (26.32) | 29.6817 |
| 2010's | 27 (28.42) | 24.3611 |
| 2020's | 4 (4.21) | 2.80 |
| Authors | Studies |
|---|---|
| Aumann, K; Brown, MP; Clarson, J; Duyster, J; El Khawanky, N; Hein, L; Hughes, A; Hughes, TP; Lopez, AF; Manz, MG; Matschulla, T; Miething, C; Myburgh, R; Shoumariyeh, K; Taromi, S; Vinnakota, JM; White, DL; Yong, ASM; Yu, W; Zeiser, R | 1 |
| Gafter-Gvili, A; Gurion, R; Raanani, P; Sherban, A; Wolach, O | 1 |
| Jia, Y; Li, C; Lin, D; Mi, Y; Wang, H; Wang, J; Wang, Z | 1 |
| Dutton, N; Fazal, S; Samhouri, Y; Tanvi, V; Ursu, S | 1 |
| Helleday, T; Henter, JI; Herold, N; Kutzner, J; Myrberg, IH; Olsen, TK; Paulin, CBJ; Rudd, SG; Sanjiv, K; Schaller, T | 1 |
| Abdelkarim, M; Becker, H; Bullinger, L; Claus, R; Döhner, K; Duyster, J; Gaidzik, VI; Hackanson, B; Kovarbasic, M; Lübbert, M; Pahl, HL; Schmidts, A; Wäsch, R; Wehrle, J; Yalcin, A | 1 |
| Andreeff, M; Benton, CB; Boddu, P; Borthakur, G; Cortes, J; Daver, N; DiNardo, CD; Garcia-Manero, G; Jabbour, EJ; Kadia, T; Kanagal-Shamanna, R; Kantarjian, H; Konopleva, M; Patel, K; Ravandi, F; Takahashi, K | 1 |
| Booth, S; Cheng, P; Craddock, C; De Santo, C; Fultang, L; Kearns, P; Keeshan, K; Mussai, F; Perry, T; Sarrou, E; Stavrou, V; Wheat, R | 1 |
| Jing, Y; Sun, L; Yang, L; Yuan, L | 1 |
| Alhan, C; Beeker, A; de Groot, M; de Weerdt, O; Hoogendoorn, M; Huls, G; Koedam, J; Kooy, Mv; Laterveer, L; van de Loosdrecht, AA; van der Helm, LH; Veeger, NJ; Vellenga, E | 1 |
| Côté, S; Momparler, LF; Momparler, RL | 1 |
| Boddy, N; Burrows, F; Pallis, M; Russell, N; Seedhouse, C; Whittall, A | 1 |
| Curik, N; Dluhosova, M; Jonasova, A; Stopka, T; Vargova, J; Zikmund, T | 1 |
| Cornelison, AM; Cortes, JE; Daver, N; Garcia-Manero, G; Jabbour, E; Kadia, T; Kantarjian, H; Ravandi, F; Teng, A | 1 |
| Carrillo, E; De Teresa, E; García, MA; Hernández, MC; Jiménez-Navarro, M; López-Ruiz, E; Marchal, JA; Perán, M; Picón-Ruiz, M; Prat, I | 1 |
| Dass, R; De Porre, P; He, J; Thomas, X; Xiu, L | 1 |
| Cao, L; Du, XJ; Fang, F; Feng, X; Hu, SY; Li, YH; Li, YP; Li, ZH; Lu, J; Ni, J; Pan, J; Su, GH; Sun, LC; Tao, YF; Wang, J; Wang, NN; Xiao, PF; Xu, LX; Xu, YY; Zhao, H; Zhao, WL | 1 |
| Al-Kali, A; Bhagavatula, K; Bogenberger, JM; Delman, DH; Foran, JM; Hansen, N; Mesa, RA; Mohan, J; Oliver, GR; Rakhshan, F; Tibes, R; Wood, T | 1 |
| Baczyńska, D; Butrym, A; Kuliczkowski, K; Mazur, G; Poręba, R; Rybka, J | 1 |
| Andel, J; Autzinger, EM; Burgstaller, S; Geissler, D; Geissler, K; Girschikofsky, M; Greil, R; Halter, B; Hojas, S; Lang, A; Machherndl-Spandl, S; Pfeilstöcker, M; Pichler, A; Pleyer, L; Rogulj, IM; Schlick, K; Sill, H; Sperr, WR; Stauder, R; Thaler, J; Voskova, D; Zebisch, A | 1 |
| Baldwin, AS; Figueroa, ME; Laurenzana, A; Melnick, A; Miller, WH; Paoletti, F; Petruccelli, LA; Pettersson, F | 1 |
| Champlin, R; de Lima, M; de Padua, L; Garcia-Manero, G; Giralt, S; Jabbour, E; Jagasia, M; Kantarjian, H; Kebriaei, P; Shpall, EJ | 1 |
| Basile, FG | 1 |
| Stone, RM | 1 |
| Aukerman, SL; Brady, H; Heise, C; Hollenbach, PW; Krushel, L; MacBeth, KJ; Nguyen, AN; Ning, Y; Richard, N; Williams, M | 1 |
| Issa, JP | 1 |
| Agathanggelou, A; Cavenagh, J; Craddock, C; Goodyear, O; McSkeane, T; Moss, P; Novitzky-Basso, I; Ryan, G; Siddique, S; Stankovic, T; Vyas, P | 1 |
| Kondoh, T; Mori, N; Motoji, T; Ohwashi, M; Okada, M; Shimura, H; Shiseki, M; Tomita, K; Wang, YH; Yoshinaga, K | 1 |
| Auffret, M; Bibault, JE; Cambier, N; Lemahieu, JM; Quesnel, B; Rose, C | 1 |
| Bose, JR; Brenet, F; Curcio, TJ; Feldman, EJ; Gergis, US; Ippoliti, CM; Mayer, SA; Moh, M; Morawa, E; Ritchie, EK; Roboz, GJ; Scandura, JM; Villegas, L | 1 |
| Al-Ali, HK; Cross, M; Hoppe, G; Jaekel, N; Junghanss, C; Krahl, R; Maschmeyer, G; Niederwieser, D | 1 |
| Chiao, JW; Hong, L; Huang, Y; Ma, X; Zou, Y | 1 |
| Borthakur, G; Brandt, M; Cortes, J; Faderl, S; Garcia-Manero, G; Kantarjian, H; Liu-Dumlao, T; Pierce, S; Quintás-Cardama, A; Ravandi, F | 1 |
| Agresta, S; Amrein, PC; Attar, EC; Ballen, KK; Borger, DR; Burke, M; Chen, YB; Edmonds, KM; Emadi, A; Fathi, AT; Foster, J; Hill, C; Iafrate, AJ; Lopez, HU; Matulis, CR; Neuberg, DS; Sadrzadeh, H; Schenkein, DP; Stone, RM; Straley, KS; Yen, KE | 1 |
| Abdel-Wahab, O; Berube, C; Coutre, S; Gallegos, L; Gotlib, JR; Greenberg, P; Levine, R; Liedtke, M; Medeiros, BC; Mitchell, BS; Pollyea, DA; Zehnder, J; Zhang, B | 1 |
| Giles, FJ | 1 |
| Bernstein, M; Momparler, LF; Momparler, RL; Shaker, S | 1 |
| Aventín, A; Brunet, S; Carnicer, MJ; Estivill, C; Lasa, A; Nomdedéu, JF; Sierra, J | 1 |
| Dörken, B; Lübbert, M; Sattler, N; Schmelz, K; Tamm, I; Wagner, M | 1 |
| Emi, N; Iwai, M; Kinoshita, T; Kiyoi, H; Naoe, T; Ohno, R; Ozeki, K | 1 |
| Chen, S; Hao, CL; Tang, KJ; Wang, JX; Wang, M; Xing, HY | 1 |
| Lübbert, M; Minden, M | 1 |
| Hackanson, B; Lübbert, M; Robbel, C; Wijermans, P | 1 |
| Camacho, LH; Chanel, S; Guernah, I; Maslak, P; Nimer, S; Pandolfi, PP; Soignet, S; Warrell, R | 1 |
| Albitar, M; Bennett, JM; de Castro, C; DiPersio, J; Helmer, R; Issa, JP; Kantarjian, H; Klimek, V; Leavitt, R; Nimer, SD; Ravandi, F; Raza, A; Rosenfeld, CS; Saba, H; Shen, L; Slack, J | 1 |
| Aung, L; Kirk, RC; Liang, S; Quah, TC; Tan, RM; Yeoh, AE | 1 |
| Fenk, R; Graef, T; Haas, R; Kobbe, G; Kuendgen, A; Zohren, F | 1 |
| Baylin, S; Carducci, M; Carraway, H; Dauses, T; Dover, G; Galm, O; Gore, SD; Grever, M; Herman, JG; Jiemjit, A; Karp, JE; Manning, J; Mays, A; Miller, CB; Murgo, A; Rudek, MA; Smith, BD; Sugar, E; Weng, LJ; Zhao, M; Zwiebel, J | 1 |
| Gattermann, N; Gräf, T; Haas, R; Hildebrandt, B; Hünerlitürkoglu, A; Kobbe, G; Kuendgen, A; Zohren, F | 1 |
| Faroun, Y; Gryn, JF; Kaplan, RB; Kennedy, M; Latsko, J; Lech, JA; Lister, J; Rossetti, JM; Shadduck, RK; Sudan, N | 1 |
| Blum, W; Byrd, J; Chan, KK; Klisovic, R; Liu, S; Liu, Z; Marcucci, G; Paschka, P; Perrotti, D; Xie, Z | 1 |
| Kalberer, CP; Langenkamp, U; Rohner, A; Siegler, U; Wodnar-Filipowicz, A | 1 |
| Bruserud, Ø; Ryningen, A; Stapnes, C | 1 |
| Dalal, J; Gonzalez, C; Kearns, GL; Peters, C; Tsao, CF | 1 |
| Baehner, RL; Bernstein, ID; Chard, RL; Hammond, D; Higgins, G; McCreadie, S; Sather, H | 1 |
| Bloomfield, CD; Collins, AJ; Peterson, BA; Vogelzang, NJ | 1 |
| Amare, M; Bodey, GP; Hewlett, JS; Linman, JW; Morrison, FS; Saiki, JH; Wilson, HE | 1 |
| Chiuten, DF; Markus, S; Van Echo, DA; Wiernik, PH | 1 |
| Mann, NS; Mauch, MJ | 1 |
| Benoit, P; Demers, J; Lin, K; Momparler, LF; Momparler, RL; Raymond, R; Rivard, GE | 1 |
| Bloomfield, CD; Coleman, M; Gottlieb, AJ; Greenberg, MS; Peterson, BA | 1 |
| Dahl, GV; Look, AT; Mauer, AM; Rivera, G | 1 |
| Case, DC | 1 |
| Chard, RL | 1 |
| Bowman, WP; Dahl, GV; Evans, WE; Kalwinsky, D; Look, AT; Rivera, G | 1 |
| Carella, AM; Marmont, AM; Santini, G | 1 |
| Brodsky, I; Bulova, S; Conroy, JF; Kahn, SB; Lebedda, J; Sklaroff, R | 1 |
| Gahrton, G | 1 |
| Breton-Gorius, J; Freund, M; Guichard, J; Katz, A; Mouthon, MA; Titeux, M; Vainchenker, W | 1 |
| Aldinucci, D; Da Ponte, A; Gattei, V; Petti, MC; Pinto, A; Zagonel, V | 1 |
| Archimbaud, E; Muus, P; Willemze, R | 1 |
| Pinto, A; Zagonel, V | 1 |
| Honders, MW; Kester, MG; Landegent, JE; Stegmann, AP; Willemze, R | 1 |
| Huijgens, PC; Krulder, JW; Neve, P; Wijermans, PW | 1 |
| Fenaux, P; Quesnel, B | 1 |
| Horton, Y; Roddie, PH; Turner, ML | 1 |
| Depil, S; Dussart, P; Prin, L; Roche, C | 1 |
| Comelli, A; Massimo, L | 1 |
| Levi, JA; Wiernik, PH | 1 |
| Chabner, BA; Chang, P; Coleman, CN; Hande, KR; Stoller, RG | 1 |
| Wiernik, PH | 1 |
| Omura, GA | 1 |
| Balas, V; Cihák, A; Cízková, J; Kohout, J; Korbová, L; Malis, F; Marek, J | 1 |
| Costanzi, JJ; Hewlett, JS; Hoogstraten, B; McCredie, KB; Morrison, FS; Saiki, JH; Stuckey, WJ; Vietti, TJ; Whitecar, J | 1 |
| Belt, J; Brenner, MK; Crom, W; Hurwitz, CA; Krance, R; Mahmoud, H; Ribeirio, R; Roberts, WM; Santana, VM; Schell, MJ | 1 |
| Abella, E; Alvarado, CS; Chauvenet, A; Dubowy, R; Harris, M; Inoue, S; Krischer, JP; Ravindranath, Y; Ritchey, AK; Wiley, J | 1 |
| McCulloch, EA; Yang, GS | 1 |
| Colly, LP; Kluin-Nelemans, JC; Richel, DJ; Willemze, R | 1 |
| Moriconi, WJ; Slavik, M; Taylor, S | 1 |
| McCulloch, EA; Smith, LJ | 1 |
| Dahl, GV; Jackson, CW; Kalwinsky, DK; Look, AT; Mirro, J | 1 |
| Gyger, M; Momparler, RL; Rivard, GE | 1 |
| Glick, JH; Kahn, SB; Knospe, WH; Soojian, M; Spiers, A | 1 |
| Arlin, Z; Baker, M; Bhalla, K; Cole, J; Graham, G; Grant, S; MacLaughlin, W | 1 |
| Bellet, RE; Custer, RP; Engstrom, PF; Mastrangelo, MJ | 1 |
10 review(s) available for azacitidine and Acute Disease
| Article | Year |
|---|---|
Maintenance therapy with hypomethylating agents for patients with acute myeloid leukemia in first remission not eligible for allogeneic hematopoietic cell transplantation: A systematic review and meta-analysis.
Topics: Acute Disease; Azacitidine; Decitabine; Disease-Free Survival; Enzyme Inhibitors; Humans; Leukemia, Myeloid; Maintenance Chemotherapy; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Treatment Outcome | 2022 |
Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: A case report and literature review.
Topics: Acute Disease; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Dendritic Cells; Hematologic Neoplasms; Humans; Male; Recombinant Fusion Proteins; Skin Neoplasms; Sulfonamides | 2021 |
How I treat patients with myelodysplastic syndromes.
Topics: Acute Disease; Aged; Azacitidine; Chelation Therapy; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Decitabine; Disease Progression; DNA Methylation; Erythropoietin; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid; Myelodysplastic Syndromes; Severity of Illness Index; Thalidomide; Transplantation, Homologous | 2009 |
Epigenetic changes in the myelodysplastic syndrome.
Topics: Acetylation; Acute Disease; Azacitidine; Cell Transformation, Neoplastic; Decitabine; DNA Methylation; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Leukemia, Myeloid; Methylation; Myelodysplastic Syndromes; Neoplasms; Protein Processing, Post-Translational | 2010 |
New drugs in acute myeloid leukemia.
Topics: Acute Disease; Adenine Nucleotides; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Bevacizumab; Boronic Acids; Bortezomib; Clofarabine; Cytosine; Decitabine; Dioxolanes; Humans; Indoles; Leukemia, Myeloid; Phthalazines; Pyrazines; Pyridines; Pyrroles; Thionucleotides | 2002 |
Decitabine in acute myeloid leukemia.
Topics: Acute Disease; Azacitidine; Decitabine; DNA Modification Methylases; Dose-Response Relationship, Drug; Epigenesis, Genetic; Humans; Leukemia, Myeloid | 2005 |
In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies.
Topics: Acute Disease; Animals; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Aberrations; Clinical Trials as Topic; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; DNA Methylation; Epigenesis, Genetic; Humans; Leukemia, Myeloid; Mice; Myelodysplastic Syndromes | 2005 |
Treatment of acute leukemia--advances in chemotherapy, immunotherapy, and bone marrow transplantation.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Age Factors; Aminoacridines; Amsacrine; Anthraquinones; Antibodies, Monoclonal; Azacitidine; Bone Marrow Transplantation; Child; Child, Preschool; Drug Administration Schedule; Etoposide; Humans; Ifosfamide; Immunotherapy; Infant; Interferons; Leukemia; Leukemia, Lymphoid; Liposomes; Middle Aged; Mitoxantrone; Naphthacenes; Prognosis; Teniposide; Transplantation, Homologous; Transplantation, Isogeneic; Vinblastine; Vindesine | 1983 |
5-Aza-2'-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends.
Topics: Acute Disease; Antineoplastic Agents; Azacitidine; Decitabine; Humans; Leukemia, Myeloid; Myelodysplastic Syndromes | 1993 |
P15INK4b gene methylation and myelodysplastic syndromes.
Topics: Acute Disease; Animals; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Carrier Proteins; Cell Cycle; Cell Cycle Proteins; Cell Differentiation; Cell Transformation, Neoplastic; Chromosomes, Human, Pair 9; Clinical Trials, Phase II as Topic; Cyclin-Dependent Kinase Inhibitor p15; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinases; Decitabine; Disease Progression; DNA Methylation; Genes, p16; Genes, Tumor Suppressor; Hematopoiesis; Humans; Leukemia, Myeloid; Mice; Myelodysplastic Syndromes; Neoplasm Proteins; Precancerous Conditions; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transforming Growth Factor beta; Tumor Suppressor Proteins | 1999 |
14 trial(s) available for azacitidine and Acute Disease
| Article | Year |
|---|---|
Targeting the arginine metabolic brake enhances immunotherapy for leukaemia.
Topics: Acute Disease; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Arginase; Arginine; Azacitidine; Humans; Immunotherapy; K562 Cells; Leukemia, Myeloid; Receptors, Chimeric Antigen; Sialic Acid Binding Ig-like Lectin 3; T-Lymphocytes; Tumor Microenvironment; Vorinostat | 2019 |
Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Daunorubicin; Decitabine; Diarrhea; DNA Methylation; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fever; Humans; Infections; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Nausea; Neutropenia; Treatment Outcome; Young Adult | 2011 |
Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Constipation; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Leukemia, Myeloid; Male; Middle Aged; Nausea; Neutropenia; Prospective Studies; Remission Induction; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2012 |
Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; fms-Like Tyrosine Kinase 3; Humans; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Myeloid; Male; Middle Aged; Mutation; Nausea; Nuclear Proteins; Nucleophosmin; Prognosis; Remission Induction; Thalidomide; Treatment Outcome; Vomiting | 2013 |
Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome.
Topics: Acetylation; Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; DNA Methylation; Drug Administration Schedule; Drug Therapy, Combination; Female; Histones; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Phenylbutyrates; Pilot Projects; Transcription, Genetic; Treatment Outcome | 2006 |
Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.
Topics: Acute Disease; Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease Progression; Disease-Free Survival; DNA Methylation; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Palliative Care; Quality of Life; Survival Rate | 2006 |
Contrasting benefits of two maintenance programs following identical induction in children with acute nonlymphocytic leukemia: a report from the Childrens Cancer Study Group.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Cyclophosphamide; Cytarabine; Humans; Leukemia; Thioguanine; Vincristine | 1984 |
Studies with anthracyclines in pediatric acute nonlymphocytic leukemia.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Antibiotics, Antineoplastic; Azacitidine; Child; Child, Preschool; Clinical Trials as Topic; Daunorubicin; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Leukemia; Male; Middle Aged; Naphthacenes; Random Allocation; Sex Factors | 1981 |
In vitro and in vivo effects of 5-aza-2'-deoxycytidine (Decitabine) on clonogenic cells from acute myeloid leukemia patients.
Topics: Acute Disease; Antineoplastic Agents; Azacitidine; Decitabine; Drug Screening Assays, Antitumor; Humans; Leukemia, Myeloid; Remission Induction; Tumor Stem Cell Assay | 1993 |
A comparative clinical trial of 5-azacytidine and guanazole in previously treated adults with acute nonlymphocytic leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Azacitidine; Digestive System; Female; Fever; Guanazole; Humans; Infusions, Parenteral; Leukemia; Leukopenia; Male; Middle Aged; Remission, Spontaneous; Time Factors; Triazoles | 1976 |
Combination therapy with 5-azacytidine plus beta-2'-deoxythioguanosine in adult acute leukemia.
Topics: Acute Disease; Adult; Azacitidine; Clinical Trials as Topic; Deoxyguanosine; Deoxyribonucleosides; Drug Therapy, Combination; Humans; Leukemia; Thionucleosides; Time Factors | 1977 |
Current strategies for treatment of acute myeloid leukemia at St Jude Children's Research Hospital.
Topics: 2-Chloroadenosine; Acute Disease; Adolescent; Adult; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Child, Preschool; Cladribine; Cytarabine; Daunorubicin; Deoxyadenosines; Etoposide; Humans; Infant; Leukemia, Myeloid, Acute; Remission Induction | 1992 |
Induction failures in childhood acute nonlymphocytic leukemia: etoposide/5-azacytidine for cases refractory to daunorubicin/cytarabine.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Clinical Trials as Topic; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia; Male | 1986 |
Clinical trial on 5-aza-2'-deoxycytidine in patients with acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Azacitidine; Cell Cycle; Cell Differentiation; Child; Clinical Trials as Topic; Decitabine; DNA, Neoplasm; Drug Evaluation; Humans; Leukemia; Methylation; Research Design | 1985 |
71 other study(ies) available for azacitidine and Acute Disease
| Article | Year |
|---|---|
Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia.
Topics: Acute Disease; Animals; Azacitidine; Cell Line, Tumor; Cells, Cultured; Cytotoxicity, Immunologic; DNA Methylation; Enzyme Inhibitors; HEK293 Cells; HL-60 Cells; Humans; Immunotherapy, Adoptive; Interleukin-3 Receptor alpha Subunit; Kaplan-Meier Estimate; Leukemia, Myeloid; Mice, Knockout; Receptors, Antigen, T-Cell; Receptors, Chimeric Antigen; Single-Chain Antibodies; Xenograft Model Antitumor Assays | 2021 |
Diagnostic challenge in mixed phenotype acute leukemia with T/megakaryocyte or T/myeloid lineages accompanied by t(3;3).
Topics: Acute Disease; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cell Lineage; Female; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Megakaryocytes; Phenotype; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sulfonamides | 2022 |
With me or against me: Tumor suppressor and drug resistance activities of SAMHD1.
Topics: Acute Disease; Animals; Antimetabolites, Antineoplastic; Autoimmune Diseases of the Nervous System; Azacitidine; Cell Line, Tumor; Cell Proliferation; Cytarabine; Decitabine; Drug Resistance; Humans; Leukemia, Myeloid; Monomeric GTP-Binding Proteins; Mutation; Nervous System Malformations; SAM Domain and HD Domain-Containing Protein 1; Survival Analysis; Treatment Outcome; Tumor Suppressor Proteins | 2017 |
The oligodendrocyte lineage transcription factor 2 (OLIG2) is epigenetically regulated in acute myeloid leukemia.
Topics: Acute Disease; Azacitidine; Blotting, Western; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Jurkat Cells; Leukemia, Myeloid; Oligodendrocyte Transcription Factor 2; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; U937 Cells | 2017 |
Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cladribine; Cytarabine; Decitabine; Drug Administration Schedule; Humans; Leukemia, Myeloid; Middle Aged; Mutation; Remission Induction; Survival Analysis; Treatment Outcome; Tumor Suppressor Protein p53 | 2018 |
Acute graft-versus-host disease in a nonhematopoietic stem cell transplantation candidate treated with decitabine followed by granulocyte colony-stimulating factor-primed peripheral blood stem cells infusion: a special entity of the disease?
Topics: Acute Disease; Antineoplastic Agents; Azacitidine; Combined Modality Therapy; Decitabine; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Transplantation Conditioning | 2014 |
Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts.
Topics: Acute Disease; Aged; Aged, 80 and over; Azacitidine; Bone Marrow; Bone Marrow Cells; Cell Count; Compassionate Use Trials; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Outcome Assessment, Health Care; Remission Induction; Retrospective Studies | 2013 |
Epigenetic action of decitabine (5-aza-2'-deoxycytidine) is more effective against acute myeloid leukemia than cytotoxic action of cytarabine (ARA-C).
Topics: Acute Disease; Aged; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Cell Survival; Cytarabine; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Drug Approval; HL-60 Cells; Humans; Leukemia, Myeloid; Middle Aged; Remission Induction; Survival Analysis; Treatment Outcome; United States; United States Food and Drug Administration | 2013 |
Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells.
Topics: Acute Disease; Adenine Nucleotides; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Azacitidine; Cell Line, Tumor; Cell Survival; Clofarabine; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; Flavonoids; Heterocyclic Compounds, 4 or More Rings; Humans; Leukemia, Myeloid; Piperidines; Purines; RNA Polymerase II; RNA, Neoplasm; Roscovitine; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
Epigenetic control of SPI1 gene by CTCF and ISWI ATPase SMARCA5.
Topics: Acute Disease; Adenosine Triphosphatases; Animals; Azacitidine; CCCTC-Binding Factor; Cell Line, Tumor; Chromosomal Proteins, Non-Histone; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Genomic Imprinting; HeLa Cells; Humans; Immunoblotting; Insulin-Like Growth Factor II; K562 Cells; Leukemia, Erythroblastic, Acute; Leukemia, Myeloid; Microscopy, Confocal; Protein Binding; Proto-Oncogene Proteins; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Long Noncoding; Trans-Activators | 2014 |
The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes.
Topics: Acute Disease; Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Outcome Assessment, Health Care; Proportional Hazards Models; Retrospective Studies | 2015 |
Cardiomyogenic differentiation potential of human endothelial progenitor cells isolated from patients with myocardial infarction.
Topics: Acute Disease; Adult; Aged; Azacitidine; Biomarkers; Blood Cells; Cell Differentiation; Cells, Cultured; Endothelial Progenitor Cells; Endothelium, Vascular; Female; Guided Tissue Regeneration; Humans; Male; Middle Aged; Myocardial Infarction; Myocytes, Cardiac; Umbilical Cord | 2014 |
Decitabine reduces transfusion dependence in older patients with acute myeloid leukemia: results from a post hoc analysis of a randomized phase III study.
Topics: Acute Disease; Aged; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Decitabine; Disease-Free Survival; Erythrocyte Transfusion; Humans; Leukemia, Myeloid; Multivariate Analysis; Outcome Assessment, Health Care; Platelet Transfusion; Randomized Controlled Trials as Topic; Remission Induction | 2015 |
Zinc finger protein 382 is downregulated by promoter hypermethylation in pediatric acute myeloid leukemia patients.
Topics: Acute Disease; Azacitidine; Cell Line, Tumor; Child; Decitabine; DNA Methylation; DNA-Binding Proteins; Down-Regulation; Enzyme Inhibitors; Female; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Jurkat Cells; K562 Cells; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Neoplasm, Residual; Prognosis; Promoter Regions, Genetic; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; Transcription Factors; U937 Cells | 2014 |
The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia.
Topics: Acute Disease; Aged; Aged, 80 and over; Anilides; Antimetabolites, Antineoplastic; Azacitidine; Biphenyl Compounds; Cell Line, Tumor; Cell Survival; Chromosomes, Human, Pair 5; Chromosomes, Human, Pair 7; Drug Synergism; Female; Hedgehog Proteins; High-Throughput Nucleotide Sequencing; HL-60 Cells; Humans; Leukemia, Myeloid; Male; Myelodysplastic Syndromes; Pyridines; RNA Interference; Signal Transduction | 2015 |
Clinical response to azacitidine therapy depends on microRNA-29c (miR-29c) expression in older acute myeloid leukemia (AML) patients.
Topics: Acute Disease; Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Gene Expression Regulation, Leukemic; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; MicroRNAs; Middle Aged; Prognosis; Remission Induction; Treatment Outcome; Young Adult | 2016 |
Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Austria; Azacitidine; Female; France; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Outcome Assessment, Health Care; Prognosis; Proportional Hazards Models; Registries; United Kingdom; United States; World Health Organization | 2016 |
Inhibition of DNA methyltransferase activates tumor necrosis factor alpha-induced monocytic differentiation in acute myeloid leukemia cells.
Topics: Acetylation; Acute Disease; Azacitidine; Cell Differentiation; Chromatin; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Enzyme Inhibitors; Histones; Humans; Leukemia, Myeloid; Monocytes; NF-kappa B; NF-kappa B p50 Subunit; Promoter Regions, Genetic; Receptors, Tumor Necrosis Factor, Type I; Receptors, Tumor Necrosis Factor, Type II; Transcription Factor RelA; Tumor Necrosis Factor-alpha; U937 Cells | 2009 |
Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia.
Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Combined Modality Therapy; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Middle Aged; Recurrence; Retrospective Studies; Transplantation, Homologous | 2009 |
Durable clinical and cytogenetic remission in an elderly patient with relapsed acute myeloid leukemia treated with low-dose lenalidomide.
Topics: Acute Disease; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Decitabine; Humans; Lenalidomide; Leukemia, Myeloid; Male; Neoplasm Recurrence, Local; Remission Induction; Thalidomide | 2009 |
A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Blotting, Western; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Survival; Decitabine; DNA Damage; DNA Methylation; Dose-Response Relationship, Drug; Flow Cytometry; Gene Expression; HL-60 Cells; Humans; Leukemia, Myeloid; Oligonucleotide Array Sequence Analysis; Protein Biosynthesis; Repressor Proteins | 2010 |
Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia.
Topics: Acute Disease; Aged; Aged, 80 and over; Amino Acid Sequence; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cluster Analysis; Female; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; K562 Cells; Leukemia, Myeloid; Male; Melanoma-Specific Antigens; Middle Aged; Myelodysplastic Syndromes; Neoplasm Proteins; Reverse Transcriptase Polymerase Chain Reaction; T-Lymphocytes, Cytotoxic; U937 Cells; Valproic Acid | 2010 |
Aberrant methylation of the RIZ1 gene in myelodysplastic syndrome and acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Base Sequence; Decitabine; DNA Methylation; DNA-Binding Proteins; Female; Gene Expression; Histone-Lysine N-Methyltransferase; HL-60 Cells; Humans; Leukemia, Myeloid; Male; Middle Aged; Molecular Sequence Data; Myelodysplastic Syndromes; Nuclear Proteins; Polymerase Chain Reaction; Promoter Regions, Genetic; Sequence Analysis, DNA; Transcription Factors; U937 Cells; Young Adult | 2011 |
Acute myocarditis induced by hypomethylating agents.
Topics: Acute Disease; Anemia, Refractory, with Excess of Blasts; Azacitidine; Decitabine; Humans; Middle Aged; Myocarditis; Troponin | 2011 |
Effect of phenylhexyl isothiocyanate on aberrant histone H3 methylation in primary human acute leukemia.
Topics: Acetylation; Acute Disease; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Case-Control Studies; Child; Decitabine; DNA Methylation; Female; Histone Deacetylase Inhibitors; Histone-Lysine N-Methyltransferase; Histones; Humans; Hydroxamic Acids; Isothiocyanates; Leukemia; Male; Middle Aged; Protein Processing, Post-Translational; Young Adult | 2012 |
Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Epigenesis, Genetic; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid; Male; Multivariate Analysis; Mutation; Prognosis; Remission Induction; Survival Analysis; Treatment Outcome | 2012 |
Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; DNA Mutational Analysis; Female; Glutarates; Granulocyte Precursor Cells; Humans; Idarubicin; Isocitrate Dehydrogenase; Leukemia, Myeloid; Male; Middle Aged; Mutation; Prospective Studies; Time Factors | 2012 |
Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2'-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells.
Topics: Acetylation; Acute Disease; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Azacitidine; Cell Division; Decitabine; Depsipeptides; DNA Methylation; DNA Replication; DNA, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Histones; HL-60 Cells; Humans; Hydroxamic Acids; Leukemia, Myeloid; Neoplasm Proteins; Peptides, Cyclic; Protein Processing, Post-Translational; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2003 |
MEIS 1 expression is downregulated through promoter hypermethylation in AML1-ETO acute myeloid leukemias.
Topics: Acute Disease; Adult; Azacitidine; Bone Marrow; Case-Control Studies; Cell Line, Tumor; Core Binding Factor Alpha 2 Subunit; Decitabine; DNA Methylation; Down-Regulation; Homeodomain Proteins; Humans; Hydroxamic Acids; Leukemia, Myeloid; Myeloid Ecotropic Viral Integration Site 1 Protein; Neoplasm Proteins; Oncogene Proteins, Fusion; Promoter Regions, Genetic; RNA, Messenger; RUNX1 Translocation Partner 1 Protein; Transcription Factors | 2004 |
Induction of gene expression by 5-Aza-2'-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms.
Topics: Acute Disease; Apoptosis; Azacitidine; Base Sequence; Cell Division; Decitabine; DNA Methylation; DNA Primers; Epithelial Cells; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid; Myelodysplastic Syndromes; Polymerase Chain Reaction | 2005 |
Expression and methylation status of the FHIT gene in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Acid Anhydride Hydrolases; Acute Disease; Azacitidine; Bone Marrow; Cell Cycle Proteins; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Leukemia, Myeloid; Myelodysplastic Syndromes; Neoplasm Proteins; Recurrence; RNA, Messenger; Tumor Suppressor Proteins | 2005 |
[5-Aza-2'-deoxycytidine enhances differentiation and apoptosis induced by phenylbutyrate in Kasumi-1 cells].
Topics: Acute Disease; Apoptosis; Azacitidine; CD11b Antigen; CD13 Antigens; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Decitabine; Dose-Response Relationship, Drug; Drug Synergism; Humans; Leukemia, Myeloid; Phenylbutyrates | 2005 |
Improved outcome in childhood acute myeloid leukemia in Singapore with the MRC AML 10 protocol.
Topics: Acute Disease; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Cytarabine; Daunorubicin; Developing Countries; Disease-Free Survival; Drug Evaluation; Etoposide; Female; Gastrointestinal Diseases; Heart Diseases; Hematologic Diseases; Humans; Infant; Infections; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Mercaptopurine; Methotrexate; Mitoxantrone; Prednisone; Remission Induction; Retrospective Studies; Singapore; Survival Analysis; Thioguanine; Treatment Outcome; Vincristine | 2007 |
Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine.
Topics: Acute Disease; Antineoplastic Agents; Azacitidine; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Middle Aged; Myelodysplastic Syndromes; Recurrence; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2007 |
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.
Topics: Acetylation; Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Dose-Response Relationship, Drug; Feasibility Studies; Female; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Phenylbutyrates; Promoter Regions, Genetic; Treatment Outcome | 2006 |
Induction of complete remission in a patient with acute myeloid leukemia refractory to high-dose chemotherapy through treatment with 5-azacytidine.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fatal Outcome; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Leukemia, Myeloid; Middle Aged; Predictive Value of Tests; Prognosis; Remission Induction | 2007 |
Treatment of acute myelogenous leukemia with outpatient azacitidine.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Drug Administration Schedule; Female; Humans; Injections, Subcutaneous; Leukemia, Myeloid; Male; Middle Aged; Outpatients; Retrospective Studies | 2006 |
Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Chromatography, Liquid; Clinical Trials, Phase I as Topic; Decitabine; Deoxycytidine; Deoxyguanosine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Humans; Leukemia, Myeloid; Tandem Mass Spectrometry | 2007 |
Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bryostatins; Cell Differentiation; Cell Line, Tumor; Cholecalciferol; Cytotoxicity, Immunologic; Decitabine; Flow Cytometry; GPI-Linked Proteins; Humans; Hydroxamic Acids; Intercellular Signaling Peptides and Proteins; Killer Cells, Natural; Leukemia, Myeloid; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin; Up-Regulation | 2007 |
Clonogenic acute myelogenous leukemia cells are heterogeneous with regard to regulation of differentiation and effect of epigenetic pharmacological targeting.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Azacitidine; Cell Cycle; Cell Differentiation; Cell Proliferation; Decitabine; DNA, Mitochondrial; Enzyme Inhibitors; Epigenesis, Genetic; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Phenylbutyrates; Thymidine; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2007 |
Azacitidine pharmacokinetics in an adolescent patient with renal compromise.
Topics: Acute Disease; Adolescent; Azacitidine; Chimerism; Dose-Response Relationship, Drug; Drug Administration Schedule; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Injections, Subcutaneous; Leukemia, Myeloid; Male; Myelodysplastic Syndromes; Recurrence; Renal Insufficiency; Treatment Outcome | 2007 |
5-Azacytidine and renal tubular dysfunction.
Topics: Acute Disease; Adolescent; Adult; Aged; Azacitidine; Bicarbonates; Glycosuria; Humans; Kidney Tubules; Leukemia; Middle Aged; Phosphorus; Polyuria; Potassium; Sodium | 1981 |
Effect of schedule on activity and toxicity of 5-azacytidine in acute leukemia: a Southwest Oncology Group Study.
Topics: Acute Disease; Adult; Azacitidine; Drug Administration Schedule; Drug Evaluation; Female; Humans; Leukemia; Male; Remission, Spontaneous; Time Factors | 1981 |
A clinical trial of pyrazofurin in combination with 5-azacytidine in acute adult nonlymphocytic leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Amides; Antibiotics, Antineoplastic; Azacitidine; Drug Evaluation; Female; Humans; Leukemia; Male; Middle Aged; Pyrazoles; Ribonucleosides; Ribose | 1981 |
Inhibitory effect of cycloheximide, somatostatin and 5-azacytidine on acute experimental pancreatitis.
Topics: Acute Disease; Animals; Azacitidine; Cycloheximide; Male; Pancreas; Pancreatitis; Rats; Somatostatin | 1981 |
Phase I study on 5-aza-2'-deoxycytidine in children with acute leukemia.
Topics: Acute Disease; Adolescent; Antineoplastic Agents; Azacitidine; Child; Child, Preschool; Cytarabine; Decitabine; Dose-Response Relationship, Drug; Drug Evaluation; Hematopoietic System; Humans; Leukemia; Male | 1981 |
5-azactidine and zorubicin for patients with previously treated acute nonlymphocytic leukemia: a Cancer and Leukemia Group B pilot study.
Topics: Acute Disease; Adult; Aged; Azacitidine; Bone Marrow; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Kidney; Leukemia; Liver; Male; Middle Aged; Pilot Projects | 1982 |
Clinical and cell kinetic studies of the effects of the epipodophyllotoxin VP16-213 during therapy of refractory acute nonlymphocytic leukemia.
Topics: Acute Disease; Adolescent; Adult; Azacitidine; Cell Division; Child; Child, Preschool; DNA, Neoplasm; Drug Resistance; Etoposide; Female; Flow Cytometry; Humans; Infant; Kinetics; Leukemia; Male; Mitosis; Podophyllotoxin | 1982 |
5-azacytidine in refractory acute leukemia.
Topics: Acute Disease; Adult; Aged; Agranulocytosis; Azacitidine; Chemical and Drug Induced Liver Injury; Humans; Infusions, Parenteral; Leukemia; Leukemia, Myeloid; Middle Aged; Muscular Diseases | 1982 |
Single-agent and combination chemotherapy with etoposide in the acute leukemias of childhood.
Topics: Acute Disease; Azacitidine; Child; Drug Therapy, Combination; Etoposide; Humans; Leukemia; Podophyllotoxin; Prednisone; Vincristine | 1982 |
Amsacrine and 5-azacytidine in acute non lymphatic leukaemia (ANLL).
Topics: Acute Disease; Adult; Aminoacridines; Amsacrine; Azacitidine; Humans; Leukemia | 1982 |
4'-(9-acridinylamino)methane-sulfon-m-anisidide (m-AMSA) and 5-azacytidine (AZA) in the treatment of relapsed adult acute leukemia.
Topics: Acute Disease; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Azacitidine; Drug Therapy, Combination; Female; Humans; Leukemia; Male; Middle Aged; Prognosis; Recurrence | 1983 |
Growth and differentiation of the human megakaryoblastic cell line (ELF-153): a model for early stages of megakaryocytopoiesis.
Topics: Acute Disease; Antigens, CD; Azacitidine; Cell Differentiation; Cell Division; Cell Line; Cytochalasin B; Cytokines; Fibroblast Growth Factor 2; Flow Cytometry; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoiesis; Humans; Leukemia, Myeloid; Megakaryocytes; Microscopy, Immunoelectron; Models, Biological; Receptors, Cytokine; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured | 1994 |
Preliminary results with 5-aza-2'-deoxycytidine (DAC)-containing chemotherapy in patients with relapsed or refractory acute leukemia. The EORTC Leukemia Cooperative Group.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Agents; Azacitidine; Decitabine; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction | 1993 |
Role of deoxycytidine kinase in an in vitro model for AraC- and DAC-resistance: substrate-enzyme interactions with deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-aza-2'-deoxycytidine.
Topics: Acute Disease; Animals; Antineoplastic Agents; Azacitidine; Binding, Competitive; Cytarabine; Decitabine; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance; In Vitro Techniques; Kinetics; Leukemia, Myeloid; Rats; Rats, Inbred BN; Tumor Cells, Cultured | 1993 |
Continuous infusion of low-dose 5-Aza-2'-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome.
Topics: Acute Disease; Aged; Aged, 80 and over; Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents; Azacitidine; Decitabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Pancytopenia | 1997 |
Primary acute myeloid leukaemia blasts resistant to cytokine-induced differentiation to dendritic-like leukaemia cells can be forced to differentiate by the addition of bryostatin-1.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Azacitidine; Bryostatins; CD40 Ligand; Cell Differentiation; Child; Cytokines; Dendritic Cells; Drug Resistance; Drug Synergism; Female; Granulocyte-Macrophage Colony-Stimulating Factor; HLA-D Antigens; Humans; Hydroxamic Acids; Immunophenotyping; In Situ Hybridization, Fluorescence; Interleukin-12; Interleukin-4; Karyotyping; Lactones; Leukemia, Myeloid; Lymphocyte Culture Test, Mixed; Macrolides; Male; Middle Aged; Neoplasm Proteins; Neoplastic Stem Cells; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2002 |
Expression of a human endogenous retrovirus, HERV-K, in the blood cells of leukemia patients.
Topics: Acute Disease; Adult; Aged; Azacitidine; Computer Systems; Endogenous Retroviruses; Female; Gamma Rays; Gene Expression Regulation, Leukemic; Gene Expression Regulation, Viral; Genes, gag; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Male; Middle Aged; Neoplastic Stem Cells; Phytohemagglutinins; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Reverse Transcriptase Polymerase Chain Reaction; Transcription, Genetic | 2002 |
[New drugs for the therapy of acute leukemia].
Topics: Acute Disease; Antineoplastic Agents; Azacitidine; Cytarabine; Daunorubicin; Doxorubicin; Drug Therapy, Combination; Guanazole; Humans; Leukemia; Lomustine; Peptichemio; Podophyllotoxin; Razoxane; Zinostatin | 1975 |
Biochemical pharmacology of cytidine analog metabolism in human leukemic cells.
Topics: Acute Disease; Adolescent; Adult; Aged; Azacitidine; Cytarabine; Cytidine Deaminase; Humans; In Vitro Techniques; Leukemia; Middle Aged; Phosphotransferases; Uridine Kinase | 1975 |
The therapy of acute leukemia in the adult: a progress report.
Topics: Acute Disease; Adult; Antineoplastic Agents; Azacitidine; Blood Transfusion; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Granulocytes; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Patient Isolation; Platelet Transfusion; Pneumonia; Prednisone; Pyrimethamine; Remission, Spontaneous; Thioguanine; Vincristine; Zinostatin | 1976 |
Inhibitory effect of various cytostatics and cycloheximide on acute experimental pancreatitis in rats.
Topics: Acrylates; Acute Disease; Animals; Antimetabolites; Azacitidine; Cycloheximide; Male; Pancreas; Pancreatitis; Rats | 1977 |
5-azacytidine in acute leukemia.
Topics: Acute Disease; Adult; Azacitidine; Bone Marrow; Central Nervous System; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Remission, Spontaneous; Time Factors | 1978 |
Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498.
Topics: Acute Disease; Adolescent; Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Azacitidine; Child; Chromosome Aberrations; Chromosome Disorders; Cytarabine; Daunorubicin; Down Syndrome; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Mercaptopurine; Methotrexate; Prednisone; Remission Induction; Thioguanine; Vincristine | 1992 |
A comparison of the lethal effects in culture of cytosine arabinoside and arabinofuranosyl-5-azacytosine acting on the blast cells fo acute myeloblastic leukemia.
Topics: Acute Disease; Antineoplastic Agents; Azacitidine; Blast Crisis; Cell Survival; Cytarabine; Humans; Leukemia, Myeloid; Tumor Cells, Cultured | 1992 |
The antileukaemic activity of 5-Aza-2 deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia.
Topics: Acute Disease; Adult; Amsacrine; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Decitabine; Drug Resistance; Female; Humans; Leukemia; Male; Middle Aged; Recurrence | 1991 |
3-Deazauridine (NSC 126849): an interesting modulator of biochemical response.
Topics: 3-Deazauridine; Acute Disease; Animals; Antineoplastic Agents; Azacitidine; Cytarabine; Decitabine; Drug Evaluation; Drug Synergism; Galactosamine; Humans; Kinetics; Leukemia; Neoplasms; Thymidine; Uridine | 1986 |
Phenotypic heterogeneity in lymphoblastic cell lines.
Topics: Acute Disease; Azacitidine; Cell Cycle; Cell Division; Cell Line; Kinetics; Leukemia, Lymphoid; Phenotype | 1986 |
Amsacrine [4'-(9-acridinylamino)-methanesulfon-m-anisidide] (m-AMSA) and 5-azacytidine (AZA) for remission reinduction in patients with relapsed adult acute nonlymphocytic leukemia. An ECOG pilot study. Eastern Cooperative Oncology Group.
Topics: Acute Disease; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Drug Evaluation; Female; Heart; Humans; Leukemia; Male; Middle Aged; Pilot Projects | 1987 |
Effect of deoxycytidine on the metabolism and cytotoxicity of 5-aza-2'-deoxycytidine and arabinosyl 5-azacytosine in normal and leukemic human myeloid progenitor cells.
Topics: Acute Disease; Azacitidine; Bone Marrow; Decitabine; Deoxycytidine; Deoxycytosine Nucleotides; DNA, Neoplasm; Hematopoietic Stem Cells; Humans; Leukemia; Neoplastic Stem Cells | 1987 |
Hepatotoxicity of 5-azacytidine (NSC-102816) (a clinical and pathologic study).
Topics: Acute Disease; Adult; Aged; Azacitidine; Chemical and Drug Induced Liver Injury; Cytidine; Female; Humans; Kupffer Cells; Liver; Male; Middle Aged; Neoplasms; Triazines | 1973 |